With the rising epidemic of obesity,metabolic syndrome,and type 2 diabetes mellitus in China,metabolic dysfunctionassociated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease.This c...With the rising epidemic of obesity,metabolic syndrome,and type 2 diabetes mellitus in China,metabolic dysfunctionassociated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease.This condition frequently occurs in Chinese patients with alcoholic liver disease and chronic hepatitis B.To address the impending public health crisis of non-alcoholic fatty liver disease and its underlying metabolic issues,the Chinese Society of Hepatology and the Chinese Medical Association convened a panel of clinical experts to revise and update the“Guideline of prevention and treatment of non-alcoholic fatty liver disease(2018,China)”.The new edition,titled“Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease(Version 2024)”,offers comprehensive recommendations on key clinical issues,including screening and monitoring,diagnosis and evaluation,treatment,and followup for metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatotic liver disease.Metabolic dysfunction-associated fatty liver disease is now the preferred English term and is used interchangeably with metabolic dysfunction-associated steatotic liver disease.Additionally,the guideline emphasizes the importance of multidisciplinary collaboration among hepatologists and other specialists to manage cardiometabolic disorders and liver disease effectively.展开更多
基金supported by the National Science and Technology Major Project of China(No:2023ZD0508700).
文摘With the rising epidemic of obesity,metabolic syndrome,and type 2 diabetes mellitus in China,metabolic dysfunctionassociated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease.This condition frequently occurs in Chinese patients with alcoholic liver disease and chronic hepatitis B.To address the impending public health crisis of non-alcoholic fatty liver disease and its underlying metabolic issues,the Chinese Society of Hepatology and the Chinese Medical Association convened a panel of clinical experts to revise and update the“Guideline of prevention and treatment of non-alcoholic fatty liver disease(2018,China)”.The new edition,titled“Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease(Version 2024)”,offers comprehensive recommendations on key clinical issues,including screening and monitoring,diagnosis and evaluation,treatment,and followup for metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatotic liver disease.Metabolic dysfunction-associated fatty liver disease is now the preferred English term and is used interchangeably with metabolic dysfunction-associated steatotic liver disease.Additionally,the guideline emphasizes the importance of multidisciplinary collaboration among hepatologists and other specialists to manage cardiometabolic disorders and liver disease effectively.
